Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

ISIS PHARMACEUTICALS, INC. (ISIS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ISIS Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Class Action Lawsuit Against ISIS Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/26/2013 | 08:35pm CET

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all purchasers of the common stock of ISIS Pharmaceuticals, Inc. ("ISIS" or the "Company") (NASDAQ:ISIS) between March 29, 2012 and October 15, 2012, inclusive (the "Class Period").

ISIS engages in the discovery and development of drugs utilizing antisense technology, primarily to treat cardiovascular, metabolic, severe and rare diseases, as well as cancer. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the safety and efficacy of the Company's flagship product, Kynamro (mipomersen sodium), for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Specifically, the Complaint alleges that defendants, through a series of materially false and misleading statements regarding the safety and efficacy of the product, and reportedly positive results from Kynamro's clinical trials, conditioned investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (FDA).

On October 16, 2012 the FDA published a clinical briefing document raising concerns regarding the safety and efficacy of Kynamro, noting among other things, abnormal growths or neoplasms developed in 3.1% of patients treated with Kynamro, as compared to only 0.9% of patients who took a placebo; that the data submitted by the Company was limited by a small sample size and a short treatment time, and that during the clinical testing two patients treated with Kynamro died of heart attacks and another patient died of acute liver failure. The FDA report concluded that this "imbalance in neoplasms will need to be assessed further in on-going and future studies and post-marketing (if approved)," and that "the potential for a contributing effect of mipomersen cannot be ruled out" in the patient deaths. As a result of these disclosures, ISIS shares declined nearly 22%, to close at $10.27 on October 16, 2012.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased ISIS common stock during the Class Period, you have certain rights, and have until February 26, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
02/23BIOGEN : The New England Journal of Medicine Publishes SPINRAZA® nusinersen Phas..
AQ
02/22IONIS PHARMACEUTICALS INC : annual earnings release
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/16BIOGEN : and Ionis Pharmaceuticals, Inc. - The New England Journal of Medicine P..
AQ
02/15IONIS PHARMACEUTICALS : to Hold 2017 Financial Results Conference Call
AQ
02/14IONIS PHARMACEUTICALS : The New England Journal of Medicine Publishes SPINRAZA® ..
BU
02/13IONIS PHARMACEUTICALS : to Hold 2017 Financial Results Conference Call
PR
01/30AKCEA THERAPEUTICS : AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With ..
AQ
01/19IONIS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/19IONIS PHARMACEUTICALS : ' Inotersen NDA Accepted for Priority Review by the FDA
AQ
More news
News from SeekingAlpha
2015Game Plan For The Week - Cramer's Mad Money (12/18/15) 
2015PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr.. 
2015Isis Pharma has had enough, name changed to Ionis Pharmaceuticals 
2015Bear Afoot? No Recession Needed For A Possible Sighting 
2015PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui.. 
Financials ($)
Sales 2017 457 M
EBIT 2017 33,4 M
Net income 2017 -10,3 M
Finance 2017 310 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 112,47
EV / Sales 2017 13,0x
EV / Sales 2018 11,2x
Capitalization 6 222 M
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 14
Average target price 57,5 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
Brett P. Monia Chief Operating Officer
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
B. Lynne Parshall Director
Joseph H. Wender Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 222
CELLTRION, INC.--.--%35 080
IQVIA HOLDINGS INC0.49%20 749
LONZA GROUP-6.95%19 560
INCYTE CORPORATION-10.05%17 877
NEKTAR THERAPEUTICS47.71%13 613